# A Phase II Study of Sunitinib or Temsirolimus in Patients With Advanced Rare Tumours

> **NCT01396408** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Canadian Cancer Trials Group** · enrollment: 137 (actual)

## Conditions studied

- Advanced Rare Tumours

## Interventions

- **DRUG:** Sunitinib
- **DRUG:** Temsirolimus

## Key facts

- **NCT ID:** NCT01396408
- **Lead sponsor:** Canadian Cancer Trials Group
- **Sponsor class:** NETWORK
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2012-02-09
- **Primary completion:** 2015-07-06
- **Final completion:** 2026-06-30
- **Target enrollment:** 137 (ACTUAL)
- **Last updated:** 2026-03-27

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01396408

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01396408, "A Phase II Study of Sunitinib or Temsirolimus in Patients With Advanced Rare Tumours". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT01396408. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*